The UK-based pharmaceutical company AstraZeneca is considering a merger with the US competitor Bristol Myers Squibb, according to a report by the Financial Times on Sunday. The discussions between the two companies have reportedly taken place over the last few months.
A merger between AstraZeneca and Bristol Myers Squibb would value the combined company at approximately $400 billion. If completed, the proposed deal would be among the largest in the history of the industry.
$400 billion
Estimated value of the joint company if the merger occurs
AstraZeneca and Bristol Myers Squibb did not immediately respond to a request for comment from CNBC.
